6/6/2012 8:17:41 AM
Amylin Pharmaceuticals Inc said U.S. health regulators have requested data on a new delivery system for its recently approved long-acting diabetes drug Bydureon. Amylin, which is seeking approval for the new pen-delivery system as an alternative to the current needle injections, said in a regulatory filing on Tuesday that it received comments from the Food and Drug Administration on its application, including a request for "incremental device-related data." The biotech company, which is taking bids from potential buyers seeking to acquire Amylin and its diabetes franchise, said it would respond to the FDA in a timely fashion.
comments powered by